RGLS4326

RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17) . RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) . RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM[1].

Product Specifications

CAS Number

[2229964-07-0]

Product Name Alternative

RG4326

UNSPSC

12352208

Target

MicroRNA

Type

Oligonucleotides

Related Pathways

Epigenetics

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/rgls4326.html

Purity

99.06

Solubility

H2O : ≥ 100 mg/mL

Smiles

OC[C@@]1(O[C@@H](N2C3=NC=NC(N)=C3N=C2)[C@]4([H])O[C@H]1C)[C@H]4OP(OC[C@]56[C@H]([C@](O[C@H]6C)([H])[C@H](N7C8=C(C(N=C(N8)N)=O)N=C7)O5)OP(OC[C@@H]9[C@H]([C@H]([C@H](N%10C(N=C(C=C%10)N)=O)O9)OC)OP(OC[C@@H]%11[C@H]([C@H]([C@H](N%12C%13=NC=NC(N)=C%13N=C%12)O%11)F)OP(OC[C@@H]%14[C@H]([C@H]([C@H](N%15C(N=C(C=C%15)N)=O)O%14)F)OP(OC[C@@H]%16[C@H]([C@H]([C@H](N%17C(NC(C=C%17)=O)=O)O%16)F)OP(OC[C@@H]%18[C@H]([C@H]([C@H](N%19C(NC(C=C%19)=O)=O)O%18)OC)OP(OC[C@]%20%21[C@H]([C@](O[C@H]%21C)([H])[C@H](N%22C(NC(C=C%22)=O)=O)O%20)OP(OC[C@@]%23%24O[C@@H](N%25C%26=C(C(N=C(N%26)N)=O)N=C%25)[C@@](O[C@H]%24C)([H])[C@@H]%23O)(S)=O)(S)=O)(S)=O)(S)=O)(S)=O)(S)=O)(S)=O)(S)=O

Molecular Formula

C95H115F3N32O51P8S8

Molecular Weight

3082.42

References & Citations

[1]Edmund C Lee, et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10 (1) :4148.